Differences in the efficacies of pazopanib and gemcitabine/docetaxel as second-line treatments for metastatic soft tissue sarcoma

Jee Hung Kim, Hyung Soon Park, Su Jin Heo, Sang Kyum Kim, Jung Woo Han, Kyoo Ho Shin, Seung Hyun Kim, Hyuk Hur, Kyung Sik Kim, Young Deuk Choi, Sunghoon Kim, Young Han Lee, Jin Suck Suh, Joong Bae Ahn, Hyun Cheol Chung, Sung Hoon Noh, Sun Young Rha, Hyo Song Kim

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: We retrospectively investigated the treatment outcomes of second-line treatment with pazopanib or gemcitabine/docetaxel in patients with advanced soft tissue sarcoma (STS). Methods: Ninety-one patients who were treated with pazopanib or gemcitabine/docetaxel for advanced STS between 1995 and 2015 were analyzed. Results: Forty-six and 45 patients received pazopanib and gemcitabine/docetaxel, respectively. The median progression-free survival for the group treated with pazopanib was 4.5 months compared with 3.0 months for the gemcitabine/docetaxel group (p = 0.593). The median overall survival for the group treated with pazopanib was 12.6 months compared with 14.2 months for the gemcitabine/docetaxel group (p = 0.362). The overall response rates (ORRs) were 6.5 and 26.7% in the pazopanib and gemcitabine/docetaxel groups, respectively. The following parameters had ORRs favoring gemcitabine/docetaxel: age ≥50 years (31.6 vs. 2.9%, p = 0.006), histologic grade 1-2 (40.9 vs. 0%, p = 0.001), and poor first-line treatment response (23.3 vs. 3.0%, p = 0.022). Gemcitabine/docetaxel was associated with better ORRs for the following histologic subtypes: leiomyosarcoma (p = 0.624), malignant fibrous histiocytoma/undifferentiated pleomorphic sarcoma (p = 0.055), and angiosarcoma (p = 0.182). However, the ORR of synovial sarcoma favored pazopanib (p = 0.99). Conclusions: The efficacies of pazopanib and gemcitabine/docetaxel as second-line treatments after doxorubicin or ifosfamide failure differed among clinical and histologic subgroups and appeared to facilitate a more personalized treatment approach for advanced STS.

Original languageEnglish
Pages (from-to)59-69
Number of pages11
JournalOncology (Switzerland)
Volume96
Issue number2
DOIs
Publication statusPublished - 2019 Feb 1

Fingerprint

docetaxel
gemcitabine
Sarcoma
Therapeutics
Synovial Sarcoma
pazopanib
Malignant Fibrous Histiocytoma
Ifosfamide
Hemangiosarcoma
Leiomyosarcoma

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kim, Jee Hung ; Park, Hyung Soon ; Heo, Su Jin ; Kim, Sang Kyum ; Han, Jung Woo ; Shin, Kyoo Ho ; Kim, Seung Hyun ; Hur, Hyuk ; Kim, Kyung Sik ; Choi, Young Deuk ; Kim, Sunghoon ; Lee, Young Han ; Suh, Jin Suck ; Ahn, Joong Bae ; Chung, Hyun Cheol ; Noh, Sung Hoon ; Rha, Sun Young ; Kim, Hyo Song. / Differences in the efficacies of pazopanib and gemcitabine/docetaxel as second-line treatments for metastatic soft tissue sarcoma. In: Oncology (Switzerland). 2019 ; Vol. 96, No. 2. pp. 59-69.
@article{7b5ee4e46e464f54a1df28497e1722b9,
title = "Differences in the efficacies of pazopanib and gemcitabine/docetaxel as second-line treatments for metastatic soft tissue sarcoma",
abstract = "Background: We retrospectively investigated the treatment outcomes of second-line treatment with pazopanib or gemcitabine/docetaxel in patients with advanced soft tissue sarcoma (STS). Methods: Ninety-one patients who were treated with pazopanib or gemcitabine/docetaxel for advanced STS between 1995 and 2015 were analyzed. Results: Forty-six and 45 patients received pazopanib and gemcitabine/docetaxel, respectively. The median progression-free survival for the group treated with pazopanib was 4.5 months compared with 3.0 months for the gemcitabine/docetaxel group (p = 0.593). The median overall survival for the group treated with pazopanib was 12.6 months compared with 14.2 months for the gemcitabine/docetaxel group (p = 0.362). The overall response rates (ORRs) were 6.5 and 26.7{\%} in the pazopanib and gemcitabine/docetaxel groups, respectively. The following parameters had ORRs favoring gemcitabine/docetaxel: age ≥50 years (31.6 vs. 2.9{\%}, p = 0.006), histologic grade 1-2 (40.9 vs. 0{\%}, p = 0.001), and poor first-line treatment response (23.3 vs. 3.0{\%}, p = 0.022). Gemcitabine/docetaxel was associated with better ORRs for the following histologic subtypes: leiomyosarcoma (p = 0.624), malignant fibrous histiocytoma/undifferentiated pleomorphic sarcoma (p = 0.055), and angiosarcoma (p = 0.182). However, the ORR of synovial sarcoma favored pazopanib (p = 0.99). Conclusions: The efficacies of pazopanib and gemcitabine/docetaxel as second-line treatments after doxorubicin or ifosfamide failure differed among clinical and histologic subgroups and appeared to facilitate a more personalized treatment approach for advanced STS.",
author = "Kim, {Jee Hung} and Park, {Hyung Soon} and Heo, {Su Jin} and Kim, {Sang Kyum} and Han, {Jung Woo} and Shin, {Kyoo Ho} and Kim, {Seung Hyun} and Hyuk Hur and Kim, {Kyung Sik} and Choi, {Young Deuk} and Sunghoon Kim and Lee, {Young Han} and Suh, {Jin Suck} and Ahn, {Joong Bae} and Chung, {Hyun Cheol} and Noh, {Sung Hoon} and Rha, {Sun Young} and Kim, {Hyo Song}",
year = "2019",
month = "2",
day = "1",
doi = "10.1159/000492597",
language = "English",
volume = "96",
pages = "59--69",
journal = "Oncology",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "2",

}

Kim, JH, Park, HS, Heo, SJ, Kim, SK, Han, JW, Shin, KH, Kim, SH, Hur, H, Kim, KS, Choi, YD, Kim, S, Lee, YH, Suh, JS, Ahn, JB, Chung, HC, Noh, SH, Rha, SY & Kim, HS 2019, 'Differences in the efficacies of pazopanib and gemcitabine/docetaxel as second-line treatments for metastatic soft tissue sarcoma', Oncology (Switzerland), vol. 96, no. 2, pp. 59-69. https://doi.org/10.1159/000492597

Differences in the efficacies of pazopanib and gemcitabine/docetaxel as second-line treatments for metastatic soft tissue sarcoma. / Kim, Jee Hung; Park, Hyung Soon; Heo, Su Jin; Kim, Sang Kyum; Han, Jung Woo; Shin, Kyoo Ho; Kim, Seung Hyun; Hur, Hyuk; Kim, Kyung Sik; Choi, Young Deuk; Kim, Sunghoon; Lee, Young Han; Suh, Jin Suck; Ahn, Joong Bae; Chung, Hyun Cheol; Noh, Sung Hoon; Rha, Sun Young; Kim, Hyo Song.

In: Oncology (Switzerland), Vol. 96, No. 2, 01.02.2019, p. 59-69.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Differences in the efficacies of pazopanib and gemcitabine/docetaxel as second-line treatments for metastatic soft tissue sarcoma

AU - Kim, Jee Hung

AU - Park, Hyung Soon

AU - Heo, Su Jin

AU - Kim, Sang Kyum

AU - Han, Jung Woo

AU - Shin, Kyoo Ho

AU - Kim, Seung Hyun

AU - Hur, Hyuk

AU - Kim, Kyung Sik

AU - Choi, Young Deuk

AU - Kim, Sunghoon

AU - Lee, Young Han

AU - Suh, Jin Suck

AU - Ahn, Joong Bae

AU - Chung, Hyun Cheol

AU - Noh, Sung Hoon

AU - Rha, Sun Young

AU - Kim, Hyo Song

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Background: We retrospectively investigated the treatment outcomes of second-line treatment with pazopanib or gemcitabine/docetaxel in patients with advanced soft tissue sarcoma (STS). Methods: Ninety-one patients who were treated with pazopanib or gemcitabine/docetaxel for advanced STS between 1995 and 2015 were analyzed. Results: Forty-six and 45 patients received pazopanib and gemcitabine/docetaxel, respectively. The median progression-free survival for the group treated with pazopanib was 4.5 months compared with 3.0 months for the gemcitabine/docetaxel group (p = 0.593). The median overall survival for the group treated with pazopanib was 12.6 months compared with 14.2 months for the gemcitabine/docetaxel group (p = 0.362). The overall response rates (ORRs) were 6.5 and 26.7% in the pazopanib and gemcitabine/docetaxel groups, respectively. The following parameters had ORRs favoring gemcitabine/docetaxel: age ≥50 years (31.6 vs. 2.9%, p = 0.006), histologic grade 1-2 (40.9 vs. 0%, p = 0.001), and poor first-line treatment response (23.3 vs. 3.0%, p = 0.022). Gemcitabine/docetaxel was associated with better ORRs for the following histologic subtypes: leiomyosarcoma (p = 0.624), malignant fibrous histiocytoma/undifferentiated pleomorphic sarcoma (p = 0.055), and angiosarcoma (p = 0.182). However, the ORR of synovial sarcoma favored pazopanib (p = 0.99). Conclusions: The efficacies of pazopanib and gemcitabine/docetaxel as second-line treatments after doxorubicin or ifosfamide failure differed among clinical and histologic subgroups and appeared to facilitate a more personalized treatment approach for advanced STS.

AB - Background: We retrospectively investigated the treatment outcomes of second-line treatment with pazopanib or gemcitabine/docetaxel in patients with advanced soft tissue sarcoma (STS). Methods: Ninety-one patients who were treated with pazopanib or gemcitabine/docetaxel for advanced STS between 1995 and 2015 were analyzed. Results: Forty-six and 45 patients received pazopanib and gemcitabine/docetaxel, respectively. The median progression-free survival for the group treated with pazopanib was 4.5 months compared with 3.0 months for the gemcitabine/docetaxel group (p = 0.593). The median overall survival for the group treated with pazopanib was 12.6 months compared with 14.2 months for the gemcitabine/docetaxel group (p = 0.362). The overall response rates (ORRs) were 6.5 and 26.7% in the pazopanib and gemcitabine/docetaxel groups, respectively. The following parameters had ORRs favoring gemcitabine/docetaxel: age ≥50 years (31.6 vs. 2.9%, p = 0.006), histologic grade 1-2 (40.9 vs. 0%, p = 0.001), and poor first-line treatment response (23.3 vs. 3.0%, p = 0.022). Gemcitabine/docetaxel was associated with better ORRs for the following histologic subtypes: leiomyosarcoma (p = 0.624), malignant fibrous histiocytoma/undifferentiated pleomorphic sarcoma (p = 0.055), and angiosarcoma (p = 0.182). However, the ORR of synovial sarcoma favored pazopanib (p = 0.99). Conclusions: The efficacies of pazopanib and gemcitabine/docetaxel as second-line treatments after doxorubicin or ifosfamide failure differed among clinical and histologic subgroups and appeared to facilitate a more personalized treatment approach for advanced STS.

UR - http://www.scopus.com/inward/record.url?scp=85055265306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055265306&partnerID=8YFLogxK

U2 - 10.1159/000492597

DO - 10.1159/000492597

M3 - Article

C2 - 30336470

AN - SCOPUS:85055265306

VL - 96

SP - 59

EP - 69

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 2

ER -